中文

瑞泰新材 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-30
ItemAmountY/Y
Revenue¥0.68B+45.5%
Gross profit¥0.06B
Operating income¥0.17B
Net income¥0.13B+320.4%
Gross margin9.1%Net margin 19.1%
Revenue Q/Q+18.9%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.61B90.9%
R&D¥0.02B2.7%
SG&A¥0.03B5.0%
Tax & other¥0.04B6.2%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

普瑞眼科宏源药业杰创智能威尔高同星科技通力科技华融化学普蕊斯富士莱艾布鲁格力博恒工精密

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies